Tecartus 0.4 – 2 × 108 cells dispersion for infusion
Sponsors
Kite Pharma Inc.
Conditions
Relapsed/Refractory Burkitt Lymphoma (BL)Relapsed/Refractory Hairy Cell LeukemiaRelapsed/Refractory Waldenstrom Macroglobulinemia (WM)Relapsed/refractory Richter Transformation (RT)
Phase 2
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)
CompletedCTIS2022-501260-18-00
Start: 2023-04-14End: 2025-01-27Target: 35Updated: 2025-02-21
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy D - Relapsed/Refractory Hairy Cell Leukemia (HCL)
CompletedCTIS2022-501262-21-00
Start: 2023-04-14End: 2024-06-25Target: 15Updated: 2023-05-26
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)
CompletedCTIS2022-501261-46-00
Start: 2023-04-14End: 2024-10-01Target: 18Updated: 2025-03-13
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia
CompletedCTIS2022-501259-10-00
Start: 2023-04-14End: 2023-06-21Target: 37Updated: 2023-05-26